- Home
- FCFS vs AXSM Comparison
FCFS vs AXSM Comparison
Compare FCFS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- AXSM
- Stock Information
- Founded
- FCFS 1988
- AXSM 2012
- Country
- FCFS United States
- AXSM United States
- Employees
- FCFS N/A
- AXSM N/A
- Industry
- FCFS Other Specialty Stores
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- AXSM Health Care
- Exchange
- FCFS Nasdaq
- AXSM Nasdaq
- Market Cap
- FCFS 5.9B
- AXSM 5.1B
- IPO Year
- FCFS 1991
- AXSM 2015
- Fundamental
- Price
- FCFS $127.91
- AXSM $105.16
- Analyst Decision
- FCFS Buy
- AXSM Strong Buy
- Analyst Count
- FCFS 3
- AXSM 15
- Target Price
- FCFS $133.50
- AXSM $170.20
- AVG Volume (30 Days)
- FCFS 290.5K
- AXSM 612.2K
- Earning Date
- FCFS 07-24-2025
- AXSM 05-05-2025
- Dividend Yield
- FCFS 1.19%
- AXSM N/A
- EPS Growth
- FCFS 21.73
- AXSM N/A
- EPS
- FCFS 6.25
- AXSM N/A
- Revenue
- FCFS $3,388,567,000.00
- AXSM $432,157,000.00
- Revenue This Year
- FCFS $2.67
- AXSM $63.30
- Revenue Next Year
- FCFS $5.58
- AXSM $61.15
- P/E Ratio
- FCFS $20.47
- AXSM N/A
- Revenue Growth
- FCFS 5.06
- AXSM 72.16
- 52 Week Low
- FCFS $100.24
- AXSM $64.11
- 52 Week High
- FCFS $135.57
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- FCFS 50.75
- AXSM 45.61
- Support Level
- FCFS $126.22
- AXSM $101.41
- Resistance Level
- FCFS $128.99
- AXSM $106.77
- Average True Range (ATR)
- FCFS 2.49
- AXSM 3.18
- MACD
- FCFS -0.58
- AXSM -0.23
- Stochastic Oscillator
- FCFS 35.91
- AXSM 39.33
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.